Biomerica Receives Home Use Approval for Fortel® Ulcer Test
Biomerica, Inc., a leading global provider of advanced diagnostic solutions, recently announced significant news. The Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Biomerica's Fortel® Ulcer Test for home use. This groundbreaking development makes it easier for individuals to conduct a critical health test privately in their homes, thereby broadening access to important diagnostic tools.
The Importance of Early Detection
The Fortel® Ulcer Test functionally detects antibodies to the Helicobacter pylori bacterium, which is a primary contributor to peptic ulcers, dyspepsia, and various gastric cancers. This quick, 10-minute test enables individuals to identify potential health issues sooner, allowing for prompt medical intervention.
Helicobacter pylori and Its Risks
Studies indicate that approximately 41% of the UAE population is infected with H. pylori, a staggering figure that underscores the urgency of early detection. For those infected, complications can arise if the condition remains untreated, with serious issues including peptic ulcers and chronic digestive pain. Additionally, H. pylori is implicated in around 80% of gastric cancer diagnoses, categorizing it as a Class 1 carcinogen by the World Health Organization.
Enhancing Access to Diagnostics
With the Fortel® Ulcer Test now approved for at-home use, Biomerica plans to collaborate with local distributors and healthcare providers in the UAE to distribute the test through pharmacies, clinics, and online platforms. This approval emphasizes Biomerica's growing influence in the Middle East, particularly following its successful introduction of other innovative diagnostic products.
CEO's Vision for Better Health
CEO Zack Irani expressed enthusiasm over this approval, stating, "With this home-use approval, we're giving people direct access to a reliable tool for early detection of a dangerous infection that could result in serious complications. This can help drive earlier and more effective medical treatment and potentially save lives." This underscores the commitment of Biomerica to enhance patient health through preventive measures and innovative solutions.
Biomerica's Commitment to Public Health
Dedicated to improving overall health outcomes, Biomerica focuses on creating affordable, innovative diagnostic products. The Fortel® Ulcer Test symbolizes the company's mission to facilitate greater access to critical health diagnostics, supporting early detection for better patient outcomes. Biomerica continues to explore advancements in its diagnostic portfolio to combat various gastrointestinal and inflammatory diseases.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc., is a distinguished biomedical technology firm focused on developing and marketing a range of cutting-edge diagnostic products that cater to both home and clinical environments. The company emphasizes enhancing individuals' health while aiming to lower healthcare expenses. With an ongoing commitment to innovation, Biomerica remains at the forefront of research and development in gastrointestinal health diagnostics.
Frequently Asked Questions
What is the Fortel® Ulcer Test?
The Fortel® Ulcer Test is a rapid, 10-minute diagnostic tool that detects antibodies to Helicobacter pylori, aiding in the identification of conditions like peptic ulcers.
Why is early detection of H. pylori important?
Early detection allows for timely treatment, reducing the risk of severe complications such as gastric cancer, which is linked to H. pylori infection.
How can individuals access the Fortel® Ulcer Test?
The test will be available through pharmacies, clinics, and online platforms, making it more accessible for at-home use.
What are the health risks associated with H. pylori?
Infections can lead to peptic ulcers, chronic digestive pain, and significantly increase the risk of gastric cancer.
What is Biomerica’s broader mission?
Biomerica aims to improve global health by providing innovative and accessible diagnostic solutions, focusing on early detection of diseases to enhance patient care.
